Tsinghua University and Bayer recently announced the signing of the sixth phase of their collaboration agreement. Wang Hongwei, Vice President of Tsinghua University, and Christian Rommel, Executive Vice President and Global Head of Research and Development at Bayer Pharmaceuticals, attended the signing ceremony.
This signing aims to further facilitate the translation of scientific research outcomes into drug discovery and development, focusing on key areas of interest such as oncology, cardiovascular and renal diseases, neurology and rare diseases, and immunology, while accelerating cutting-edge research across the pharmaceutical value chain.
Wang Hongwei noted that over the past sixteen years, Tsinghua and Bayer have built a strong and productive partnership that has continuously advanced scientific discovery and pharmaceutical innovation. Two parties have jointly launched impactful research targeting major global health challenges, setting a model for deep, full-chain collaboration between Chinese universities and international pharmaceutical companies. The signing of the sixth-phase agreement marked an important milestone in accelerating the translation of basic research into new therapies. We hope both sides will continue to leverage their strengths to drive original innovation and support the sustainable development of global healthcare.
Christian Rommel stated that China’s innovation ecosystem is advancing rapidly, marked by continuous breakthroughs in research and drug development. He noted that this progress reflects the dedication and collaboration of scientists and innovators. He added that Bayer’s long-standing partnership with Tsinghua University has become a model for collaboration between global pharmaceutical companies and Chinese academic institutions. The partnership will continue pushing the boundaries of science and bringing forward groundbreaking new therapies.
Under the agreement, Bayer will continue to provide funding and support for joint research projects over the next three years, as well as to scientists at THU in recognition of their outstanding contributions in life sciences and pharmaceutical innovation, and further enhance scientific research exchanges and discussions between the two parties.
Since 2009, Bayer has been at the forefront of establishing scientific research collaboration with THU. Over the past 16 years, this partnership has resulted in 75 joint research projects. In 2022, Bayer and THU initiated the Bayer Microfunding program to further enhance the translation of early scientific research, with nine projects receiving funding support in the past three years.
Editor: Li Han
